HDAC9 and acute myeloid leukemia: A combination of WEE1 and HDAC inhibitors has been previously shown to be effective in human acute myeloid leukemia cells with various genetic mutations, regardless of TP53 mutations, and this might be worth exploring as a treatment option in this population45.